Relmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2021 Financial Results

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/24/2026

1. SPCX
2. FDX
3. ABBV
4. META
5. SPY
6. IBM
7. NKE
8. MU
9. PFE
10. AWK

Go back to Relmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2021 Financial Results

Relmada Therapeutics (RLMD) Tops Q4 EPS by 3c

March 23, 2022 4:13 PM EDT

Relmada Therapeutics (NASDAQ: RLMD) reported Q4 EPS of ($1.80), $0.03 better than the analyst estimate of ($1.83).

For earnings history and earnings-related data on Relmada Therapeutics (RLMD) click here.

... More